Johnson & Johnson ends talks to buy Actelion

Johnson & Johnson said Tuesday it has ending talks to buy Swiss drugmaker Actelion Pharmaceuticals.

The New Brunswick, New Jersey-based health care giant said it was unable to reach a deal that would have created "adequate value" for its shareholders. Last month, it said the two were in early-stage about a possible deal.

Actelion late Tuesday confirmed the negotiations with Johnson & Johnson had been broken off. It added, however, that it was in talks "another party regarding a possible strategic transaction." It gave no further details.

Johnson & Johnson develops drugs and makes and other . It is behind such brands as Band-Aids, Tylenol and biologic immune disorder drug Remicade.

Actelion Pharmaceuticals Ltd. makes high blood pressure medicines that treat arteries in the lung and around the heart.


Explore further

Johnson & Johnson to buy Abbott's vision unit for $4.33B

© 2016 The Associated Press. All rights reserved.

Citation: Johnson & Johnson ends talks to buy Actelion (2016, December 14) retrieved 23 May 2022 from https://medicalxpress.com/news/2016-12-johnson-actelion.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors